Diabetes

Could continuous glucose monitoring (CGM) soon become the norm in primary care? Once considered a specialty tool reserved for endocrinologists, CGM is now recommended far earlier in diabetes treatment — even for patients with type 2 diabetes on basal insulin alone. Despite these guideline shifts, primary care adoption has lagged. …

Could the conventional “lifelong treatment” model for type 2 diabetes be rethought? Recent trials suggest that short‑term intensive therapy may offer more than transient glycemic control—it might trigger lasting remission in newly diagnosed patients. Such interventions, combining aggressive pharmacologic therapy or insulin with lifestyle change, show potential to preserve β‑cell …

Could something as simple as a mineral or vitamin really shift the trajectory of type 2 diabetes? It’s a question both patients and clinicians increasingly ask as supplements gain popularity and more studies explore their potential benefits. While standard treatments remain foundational, micronutrients like magnesium and vitamin D have sparked …

When treating patients with diabetes, lifestyle advice such as “eat healthy” and “stay active” is often routine. But what if we took that a step further and issued a formal exercise prescription — in other words, ordering physical activity like we would a drug? Recent research suggests that a structured …

In diabetes care, “therapeutic inertia” refers to the failure to escalate or modify treatment when a patient’s glucose control is suboptimal. Even now — when newer, more effective treatments and monitoring tools are widely available — therapeutic inertia in diabetes remains a stubborn barrier. Providers often wait too long before …

Imagine a virtual version of yourself, a “mirror you” inside a computer, where doctors and you can test different treatments, diets, or lifestyle changes — without any risk. This is not science fiction anymore. In recent years, researchers have begun applying the concept of “digital twins diabetes” — virtual patient …

Explore the pros and cons of GLP-1 drugs in managing diabetes and obesity, balancing benefits like weight loss against side effects and costs.